What should you know about mogamulizumab mycosis fungoides?

Mycosis fungoides is a type of cutaneous T-cell lymphoma in which abnormal T cells collect in the skin. Mogamulizumab is a monoclonal antibody designed to bind a marker on certain immune cells and help the body remove them. It is given by infusion under specialist supervision and is considered according to disease extent, previous treatments, symptoms, general health, and transplant plans. Skin-directed options such as topical corticosteroids, narrowband UVB phototherapy, or PUVA therapy may still have a role for some patterns of disease.

Your team will review your diagnosis, blood tests, medicines, infections, and treatment history before each infusion. Tell them about rash, fever, cough, diarrhoea, liver problems, autoimmune disease, or any planned transplant. Keep the skin moisturised as advised, avoid scratching lesions, and follow instructions about infection precautions. Attend laboratory checks and appointments even if the skin looks better, because treatment decisions also depend on blood counts and other organ monitoring.

Seek urgent help for trouble breathing, facial swelling, faintness, chest pain, or a rapidly spreading rash during or after an infusion. Contact the treatment team promptly for fever, chills, painful skin, mouth sores, unusual bleeding, yellowing of the skin, severe diarrhoea, or a new blistering rash. Some skin reactions can be serious and need assessment rather than another cream at home.

Ask why mogamulizumab is being recommended, how response will be assessed, how infusion reactions are managed, and how it affects future transplant options. Discuss whether phototherapy or topical treatment remains useful and which symptoms should trigger a same-day call.